- Home
- TOUR vs CNTX Comparison
TOUR vs CNTX Comparison
Compare TOUR & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOUR
- CNTX
- Stock Information
- Founded
- TOUR 2006
- CNTX 2015
- Country
- TOUR China
- CNTX United States
- Employees
- TOUR N/A
- CNTX 9
- Industry
- TOUR Transportation Services
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- TOUR Consumer Discretionary
- CNTX Health Care
- Exchange
- TOUR Nasdaq
- CNTX Nasdaq
- Market Cap
- TOUR 97.8M
- CNTX 102.9M
- IPO Year
- TOUR 2014
- CNTX 2021
- Fundamental
- Price
- TOUR $0.86
- CNTX $1.11
- Analyst Decision
- TOUR
- CNTX Strong Buy
- Analyst Count
- TOUR 0
- CNTX 7
- Target Price
- TOUR N/A
- CNTX $5.40
- AVG Volume (30 Days)
- TOUR 162.9K
- CNTX 440.2K
- Earning Date
- TOUR 12-04-2025
- CNTX 11-05-2025
- Dividend Yield
- TOUR 4.45%
- CNTX N/A
- EPS Growth
- TOUR N/A
- CNTX N/A
- EPS
- TOUR 0.03
- CNTX N/A
- Revenue
- TOUR $75,532,120.00
- CNTX N/A
- Revenue This Year
- TOUR $12.27
- CNTX N/A
- Revenue Next Year
- TOUR $10.18
- CNTX N/A
- P/E Ratio
- TOUR $24.32
- CNTX N/A
- Revenue Growth
- TOUR 7.57
- CNTX N/A
- 52 Week Low
- TOUR $0.75
- CNTX $0.49
- 52 Week High
- TOUR $1.18
- CNTX $2.25
- Technical
- Relative Strength Index (RSI)
- TOUR 50.07
- CNTX 46.80
- Support Level
- TOUR $0.80
- CNTX $1.04
- Resistance Level
- TOUR $0.86
- CNTX $1.15
- Average True Range (ATR)
- TOUR 0.03
- CNTX 0.09
- MACD
- TOUR 0.00
- CNTX -0.03
- Stochastic Oscillator
- TOUR 80.89
- CNTX 19.70
About TOUR Tuniu Corporation
Tuniu Corp is an online leisure travel company. The company is engaged in the provision of travel-related services in the People's Republic of China. It offers a large selection of packaged tours, including organized tours and self-guided tours, as well as travel-related services for leisure travelers. The company's organized tours provide pre-arranged itineraries, transportation, accommodations, entertainment, meals, and tour guide services. Its self-guided tours consist of combinations of flights and hotel bookings and other optional add-ons. The company derives almost all of its revenue from PRC.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.